全球经动脉化疗栓塞市场规模、份额、成长分析、按产品、最终用户、技术 - 产业预测 2024-2031

2022年全球经动脉化疗栓塞市场规模为168.8亿美元，预计将从2023年的178.1亿美元成长到2031年的273.3亿美元，预测期内（2024-2031年）复合年增长率为5.5%。

在多种因素的推动下，全球经动脉化疗栓塞 (TACE) 市场正在经历显着的成长和演变。 TACE 是一种主要用于治疗肝癌的微创手术，由于全球肝癌发生率不断上升，其需求激增。饮酒量增加、乙型和丙型肝炎感染流行以及生活方式的改变等因素导致肝癌负担不断增加。此外，医疗技术和技术的进步提高了 TACE 手术的有效性和安全性，进一步推动了市场的扩张。此外，越来越多的联合疗法（包括 TACE 与射频消融或免疫疗法等其他疗法相结合）的采用正在扩大其应用范围并推动市场成长。此外，一些国家对 TACE 手术有利的报销政策，加上正在进行的改善治疗结果的研究和开发倡议，预计将维持市场动能。然而，某些地区先进医疗设施的可及性有限以及 TACE 手术相关的高成本等挑战可能会在一定程度上阻碍市场成长。总体而言，随着不断创新和对个人化医疗的日益关注，全球 TACE 市场预计将在可预见的未来进一步发展。

目录

执行摘要

• 市场概况
• 命运之轮

研究方法论

• 资讯采购
• 二手和主要资料来源
• 市场规模估计
• 市场假设与限制

母公司市场分析

• 市场概况
• 市场规模
• 市场动态
  • 司机
  • 机会
  • 限制
  • 挑战

主要市场洞察

• 技术分析
• 定价分析
• 供应链分析
• 价值链分析
• 市场生态系统
• 智慧财产权分析
• 贸易分析
• 启动分析
• 原料分析
• 创新矩阵
• 管道产品分析
• 总体经济指标
• 顶级投资分析
• 成功的关键因素
• 竞争程度

市场动态与展望

• 市场动态
  • 司机
  • 机会
  • 限制
  • 挑战
• 监管环境
• 波特分析
• 对未来颠覆的特别见解

按产品分類的全球经动脉化疗栓塞市场

• 市场概况
• 医院
• 门诊手术中心
• 专科诊所

按最终用户分類的全球经动脉化疗栓塞市场

• 市场概况
• 草莓
• 苹果
• 芒果
• 混合水果混合物
• 柑橘
• 异国情调的水果

按技术分類的全球经动脉化疗栓塞市场

• 市场概况
• 基于碘化油的 TACE
• 药物洗脱珠 TACE 技术

全球经动脉化疗栓塞市场规模（按地区）

• 市场概况
• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 欧洲其他地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 亚太其他地区
• 拉丁美洲
  • 巴西
  • 拉丁美洲其他地区
• 中东和非洲 (MEA)
  • 海湾合作委员会国家
  • 南非
  • MEA 的其余部分

竞争格局

• 前 5 名玩家比较
• 2023 年关键参与者的市场定位
• 主要市场参与者所采取的策略
• 最佳制胜策略
• 近期市集活动
• 主要公司市占率 (%), 2023

主要公司简介

• Boston Scientific Corporation (US)
• Terumo Corporation (Japan)
• Cook Medical (US)
• Cardinal Health (US)
• Becton, Dickinson and Company (US)
• Guerbet (France)
• AngioDynamics, Inc. (US)
• SIRtex Medical Inc. (Australia)
• Merit Medical Systems Inc. (US)
• Varian Medical Systems, Inc. (US)
• Microvena Therapeutics, Inc. (US)
• RadioMed LLC (US)
• IGT Laboratories (US)
• MicroCath, Inc. (US)
• Spectranetics, Inc. (US)
• Penumbra, Inc. (US)
• Oncotreat SA (Switzerland)
• Vascular Dynamics, Inc. (US)
• Shanghai Jahva Medical Co., Ltd. (China)
• Hangzhou Micro-Tech Co., Ltd. (China)

Global Transarterial Chemoembolization Market size was valued at USD 16.88 billion in 2022 and is poised to grow from USD 17.81 billion in 2023 to USD 27.33 billion by 2031, growing at a CAGR of 5.5% in the forecast period (2024-2031).

The global transarterial chemoembolization (TACE) market is experiencing significant growth and evolution driven by a multitude of factors. TACE, a minimally invasive procedure used primarily in the treatment of liver cancer, has witnessed a surge in demand due to the rising incidence of liver cancer worldwide. Factors such as increasing alcohol consumption, prevalence of hepatitis B and C infections, and changing lifestyles contribute to the growing burden of liver cancer. Additionally, advancements in medical technology and techniques have enhanced the efficacy and safety of TACE procedures, further fueling market expansion. Moreover, the rising adoption of combination therapies, including TACE in conjunction with other treatments such as radiofrequency ablation or immunotherapy, is broadening the scope of its application and driving market growth. Furthermore, favorable reimbursement policies for TACE procedures in several countries, coupled with ongoing research and development initiatives to improve treatment outcomes, are expected to sustain market momentum. However, challenges such as limited accessibility to advanced healthcare facilities in certain regions and the high cost associated with TACE procedures may hinder market growth to some extent. Overall, with continuous innovations and a growing focus on personalized medicine, the global TACE market is poised for further advancement in the foreseeable future.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Transarterial Chemoembolization Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Transarterial Chemoembolization Market Segmental Analysis

The global transarterial chemoembolization market is segmented into four major segments i.e. by end-user, product type, technology, and region. Based on end-user, it is divided into hospitals, ambulatory surgical centers, specialty clinics. Based on product type, it is bifurcated as catheters, guidewires, microcatheters, embolic agents, chemotherapeutic agents. Based on technology it is segregated into, lipiodol-based TACE, drug-eluting bead TACE technology. Based on region, the market is segmented into North America, Europe, Asia-Pacific, Latin America, Middle East & Africa.

Drivers of the Global Transarterial Chemoembolization Market

The global rise in liver cancer cases and the need for treatments like TACE. Furthermore, as medical procedures continue to advance, the precision and effectiveness of these treatment methods are enhanced, making them more appealing to both patients and doctors. Because minimally invasive techniques assist patients avoid the discomfort associated with traditional treatment approaches, they have also emerged as important drivers of TACE.

Restraints in the Global Transarterial Chemoembolization Market

One of the main market barriers in this instance is the variety of individuals with liver cancer cases and their complexity as a result of differing treatment responses. The degree of intricacy linked with TACE has the potential to limit its applicability and need a customized approach, which might eventually impede its widespread adoption. Strict national restrictions regarding the authorization and payment of medical operations present additional difficulty and limitation. Prolonged regulatory procedures and disparities in reimbursement techniques might make it difficult to integrate TACE into ordinary health care delivery.

Market Trends of the Global Transarterial Chemoembolization Market

The movement in liver cancer treatment toward customized care. Healthcare professionals are investigating tailored TACE depending on patient characteristics and overall health state, including tumor kinds. The general move toward precision medicine to optimize patient outcomes is supported by this trend. The TACE market is also seeing a significant trend in technical improvements. This enhances TACE's performance, which is a continuous research project to increase its accuracy and potency. The most recent advancements in drug-eluting bead and imaging technologies, together with embolic agents, enable to target malignant spots so that therapy can be successful with the least amount of harm to surrounding tissues and organs.

Table of Contents

Executive Summary

• Market Overview
• Wheel of Fortune

Research Methodology

• Information Procurement
• Secondary & Primary Data Sources
• Market Size Estimation
• Market Assumptions & Limitations

Parent Market Analysis

• Market Overview
• Market Size
• Market Dynamics
  • Drivers
  • Opportunities
  • Restraints
  • Challenges

Key Market Insights

• Technology Analysis
• Pricing Analysis
• Supply Chain Analysis
• Value Chain Analysis
• Ecosystem of the Market
• IP Analysis
• Trade Analysis
• Startup Analysis
• Raw Material Analysis
• Innovation Matrix
• Pipeline Product Analysis
• Macroeconomic Indicators
• Top Investment Analysis
• Key Success Factor
• Degree of Competition

Market Dynamics & Outlook

• Market Dynamics
  • Drivers
  • Opportunities
  • Restraints
  • Challenges
• Regulatory Landscape
• Porters Analysis
  • Competitive rivalry
  • Threat of Substitute Products
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers
• Skyquest Special Insights on Future Disruptions
  • Political Impact
  • Economic Impact
  • Social Impact
  • Technical Impact
  • Environmental Impact
  • Legal Impact

Global Transarterial Chemoembolization Market by Product

• Market Overview
• Hospitals
• Ambulatory Surgical Centers
• Specialty Clinics

Global Transarterial Chemoembolization Market by End-User

• Market Overview
• Strawberry
• apple
• mango
• mixed fruit blends
• citrus
• and exotic fruits

Global Transarterial Chemoembolization Market by Technology

• Market Overview
• Lipiodol-based TACE
• Drug-Eluting Bead TACE Technology

Global Transarterial Chemoembolization Market Size by Region

• Market Overview
• North America
  • USA
  • Canada
• Europe
  • Germany
  • Spain
  • France
  • UK
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America
  • Brazil
  • Rest of Latin America
• Middle East & Africa (MEA)
  • GCC Countries
  • South Africa
  • Rest of MEA

Competitive Landscape

• Top 5 Player Comparison
• Market Positioning of Key Players, 2023
• Strategies Adopted by Key Market Players
• Top Winning Strategies
  • By Development
  • By Company
  • By Year
• Recent Activities in the Market
• Key Companies Market Share (%), 2023

Key Company Profiles

• Boston Scientific Corporation (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Terumo Corporation (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cook Medical (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cardinal Health (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Becton, Dickinson and Company (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Guerbet (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AngioDynamics, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• SIRtex Medical Inc. (Australia)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merit Medical Systems Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Varian Medical Systems, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Microvena Therapeutics, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• RadioMed LLC (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• IGT Laboratories (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• MicroCath, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Spectranetics, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Penumbra, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Oncotreat SA (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Vascular Dynamics, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Shanghai Jahva Medical Co., Ltd. (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hangzhou Micro-Tech Co., Ltd. (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments